Argentina’s La Pampa province to open drug production facility in 2021



The House of Representatives of the province of La Pampa in Argentina last week approved setting up a trust for the creation of an oncology drug production plant in the city of General Pico. The project expects to obtain approval for its dry medicines within 5 to 6 months, and to begin production next year.

The facility will produce drugs for La Pampa at costs 20% to 30% lower, with the possibility of marketing its products to the rest of the country and other Latin American markets.

According to a report published earlier this year, Argentina’s National Agency of Public Laboratories (ANLAP) spans a network of 34 public drug production laboratories, which produced 370 million units during 2019.

Reference:

Related news
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
US-based employee management and risk consulting specialist Mercer LLC revealed that its health management and welfare team is working with Swiss major Roche’s China unit to innovate new commercial health insurance products.
  • 1585634879967
  • China
  • Deals
China based biotech I-Mab (Nasdaq.IMAB) announced that a strategic partnership agreement has been signed with Kalbe Genexine Biologics (KG Bio), a joint venture between Indonesia’s Kalbe Farma Tbk and South Korea’s Genexine Inc​.
Japan-based Takeda Pharmaceutical Co., Ltd’s China unit is sponsoring a "Caring for Multiple Myeloma Patients" program launched by the China Primary Health Care Foundation (CPHCF) in March.
Suzhou-based biotech Innovent Biologics (HKEX.01801) announced its anti-programmed death-1 (PD-1) inhibitor Tyvyt (sintilimab) has obtained US FDA orphan drug designation (ODD).
Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot


Analytics Snapshot